Selank: What the Evidence Actually Shows

Grade C in the WestNo US pathway

Status first

Selank has no route to legal supply in the United States. It is not FDA approved, and unlike Semax it was not among the seven compounds reviewed at the July 2026 advisory committee meeting. Nothing is currently pending for it.

The short version

A synthetic analog of tuftsin, a naturally occurring immunomodulatory peptide.
Developed in Russia and used there as an anxiolytic.
Often sold blended with Semax, which is a separate compound with a separate status.
No Western trial data and no US pathway.

What it is

Selank is a tuftsin analog reported to influence GABAergic and serotonergic signalling, and to affect BDNF expression. The claimed profile is anxiolytic without sedation or dependence, which would be genuinely useful if established.

The evidence problem

The same issue as Semax, one step further along. The Russian clinical literature exists, it is largely unavailable in English, it has not been independently replicated, and there is no Western regulatory review to lean on. Unlike Semax, there is not even a pending FDA process.

What this will not do

It will not treat a diagnosed anxiety disorder, and it should not be used to defer treatment that would help.
It will not become legally available through any process currently underway.

Full library · Safety and sourcing · Reconstitution calculator · Compound index